Hematology Oncology market

1
Hematology Oncology Market Trends, Size, Share,
Demands, Overview, Growth, Revenue and Forecast
to 2030
sales_at_delvens.com www.delvens.com
2
Sternal Closure Systems Market Trends Forecast
Till 2030
Hematology Oncology Market, by Hematology Product
(Hematology Analyzers, Hematology Reagents, Flow
Cytometers, Hematology Cell Counters, Slide
Strainers, Coagulation Analyzers, Hematology
Testing, Centrifuges, Hemoglobin meters, Others),
Oncology Drug Class Type (Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy),
Oncology Indication (Lung Cancer, Stomach Cancer,
Colorectal Cancer, Breast Cancer, Prostate
Cancer, Liver Cancer, Esophagus Cancer, Cervical
Cancer, Kidney Cancer, Bladder Cancer, Others),
end users, and region (North America, Europe,
Asia-Pacific, Middle East and Africa and South
America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/hematology
-oncology-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
Hematology oncology is a medical specialty that
focuses on the diagnosis, treatment, and
management of blood disorders (hematology) and
cancer (oncology). Hematology oncologists are
trained to handle conditions such as leukemia,
lymphoma, multiple myeloma, and other blood
related cancers, as well as solid tumors. They
use a combination of chemotherapy, radiation
therapy, targeted therapy, immunotherapy, and
other advanced treatments to provide
comprehensive care to patients with these
conditions. The hematology oncology market is
expected to grow during the forecast period. This
growth can be attributed to the rise in the
prevalence of lymphoma and myeloma, rise in the
healthcare infrastructure and rise in the
geriatric population all over the world.
Moreover, the availability of more sophisticated
molecular techniques for the diagnosis of hemato
oncology has also increased. In addition,
increased demand for laboratory automation, and
more awareness of preventative healthcare are
expected to drive the market during the forecast
period. Purchase this Report
https//www.delvens.com/checkout/hematology-oncolo
gy-market
sales_at_delvens.com
www.delvens.com
4
Key Findings
The Hematology Oncology market is segmented into
Product, drug class type, oncology indication,
end users, and region Based on the product, the
market is segmented into hematology analyzers,
hematology reagents, flow cytometers, hematology
cell counters, slide strainers, coagulation
analyzers, hematology testing, centrifuges,
hemoglobin meters, others. The hematology
analyzers dominated the market in this
segment. Based on the drug class type, the
market is segmented into chemotherapy, targeted
therapy, immunotherapy, hormonal therapy.
sales_at_delvens.com
www.delvens.com
5
Key Findings
Based on oncology indication, the market is
bifurcated into lung cancer, stomach cancer,
colorectal cancer, breast cancer, prostate
cancer, liver cancer, esophagus cancer, cervical
cancer, kidney cancer, bladder cancer, others.
Leukemia dominated the market in this segment.
This is due to the high incidence of leukemia,
the development of new leukemia treatments, and
the increased demand for personalized cancer
therapies. The market is also divided into
various regions such as North America, Europe,
Asia-Pacific, South America, and Middle East and
Africa. North America is estimated to account for
the largest market share during the forecast
period. Inquire Before Buying
https//www.delvens.com/Inquire-before-buying/hema
tology-oncology-market
sales_at_delvens.com
www.delvens.com
6
Competitive Landscape

• Agilent Technologies Inc.
• Beijing Genomics Institute
• Caris Life Sciences
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd.
• Foundation Medicine Inc.
• Illumina, Inc.
• Myriad Genetics Inc.
• Oxford Nanopore Technologies plc.

• PacBio
• Paradigm Diagnostics Inc.
• Partek Incorporated
• Perkin Elmer Inc.
• Qiagen
• Thermo Fisher Scientific Inc.

sales_at_delvens.com
www.delvens.com
7
Recent Developments
In June 2022, Thermo Fisher Scientific Inc.
expanded its extensive line of automated
connective tissue disease tests by releasing the
new EliA RNA Pol III and EliA Rib-P blood tests
to assist in the diagnosis of Systemic Sclerosis
and Systemic Lupus Erythematosus (SLE).  In
2022, F. Hoffman-La Roche Ltd. Received FDA
approval for the cobras EZH2 mutation test as a
companion diagnostic for patients with follicular
lymphoma.
sales_at_delvens.com
www.delvens.com
8
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com